What is the Ilyang Pharmaceutical Co., Ltd. stock price forecast?

Ilyang Pharmaceutical Co., Ltd. is currently trading at ₩11,830. View real-time AI analysis on Alpha Lenz.

What is Ilyang Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Ilyang Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Ilyang Pharmaceutical Co., Ltd.'s P/E ratio?

Ilyang Pharmaceutical Co., Ltd.'s P/E ratio is 20.7.

Ilyang Pharmaceutical Co., Ltd.

KRX · 007570

₩11,830

Ask about Ilyang Pharmaceutical Co., Ltd.'s future dividend policy...

Alpha Chat Insight

“Ilyang Pharmaceutical Co., Ltd. trades at a P/E of 20.7 (fair value) with modest ROE of 4.7%.”

Ask for details →

Company Overview

Ilyang Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, known for its dedication to research and development in healthcare solutions. The company focuses on the creation and distribution of a wide array of medical products, including prescription drugs, over-the-counter medicines, and other therapeutic solutions aimed at improving public health outcomes. Established in South Korea, Ilyang Pharmaceutical has a significant impact in the fields of oncology, antibiotics, and hypertension, among other therapeutic areas, with substantial investments in developing innovative treatments. Its presence serves both the domestic market and international spheres, highlighting its role as a critical component in the global healthcare supply chain. Ilyang Pharmaceutical Co., Ltd. holds market significance by contributing to advancements in medical science and pharmaceutical infrastructure, catering to diverse healthcare needs, and aiming to enhance the quality of life for patients worldwide.

CEO김동연, 정유석

Websitehttps://home.ilyang.co.kr

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees670

Company Statistics

FY 2024

Profile

₩225,783,405,120Market Cap

₩268,861,229,570Revenue

19.09MShares Out

670Employees

Margins

41.46%Gross

9.36%EBITDA

4.09%Operating

4.57%Pre-Tax

3.91%Net

Valuation

20.73P/E

0.89P/B

0.79EV/Sales

12.70EV/EBITDA

-6.07P/FCF

Growth (CAGR)

-10.21%Rev 3Yr

-3.70%Rev 5Yr

-35.52%Op Inc 3Yr

-19.48%Op Inc 5Yr

-26.02%Net Inc 3Yr

-11.72%Net Inc 5Yr

Returns

2.67%ROA

4.72%ROE

3.86%ROIC

Financial Health

₩4,295,449,490Cash & Cash Equivalents

₩185,339,390,630Net Debt

78.50%Debt/Equity

4.18Interest Cov

Alpha Chat Insight

“Ilyang Pharmaceutical Co., Ltd. trades at a P/E of 20.7 (fair value) with modest ROE of 4.7%.”

Ask for details →

Frequently Asked Questions

Ilyang Pharmaceutical Co., Ltd. (ticker: 007570) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 670 employees. Market cap is $225.8B.

The current price is ₩11,830 with a P/E ratio of 20.73x and P/B of 0.89x.

ROE is 4.72% and operating margin is 4.09%. Annual revenue is $268.9B.